Description
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL).
Cat.No
A590
Name
Urelumab
Chemical Properties
CAS
934823-49-1
Synonyms
BMS 663513;20H4.9-IgG4;10C7;Urelumab;Research Grade Urelumab(DHG11002);Research Grade Urelumab(DHG11002);anti-4-1BB antibody;anti-4-1BB antibody;BMS-663513;BMS-663513;Urelumab (anti-TNFRSF9);Urelumab (anti-TNFRSF9);BMS-663513|||BMS-66513;BMS-663513|||BMS-66513
pH value
Corresponds to reference standard: PASS
Non-reduced CE-SDS
>95%
SEC-HPLC
>95%
Isoelectric Point
Corresponds to reference standard
Bacterial Endotoxins Test
Residual Proteins of Host Cell
Exogenous Residual DNA
Residual protein A
Biological Activity
Osmolality
Corresponds to reference standard: PASS
Peptide mapping
Corresponds to reference standard: PASS
N-terminal sequence
Corresponds to reference standard: PASS
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
Tel: +86-21-58447131Fax: +86-21-61642470Email:
Website:
